|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01501 INT MEDICAL
Nominal 
33.640 +0.660 (+2.001%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | -- | -- | 851,954 | 752,836 | 585,883 | 464,675 |
| Cost of Sales | -- | -- | (314,292) | (314,766) | (253,397) | (188,930) |
| Gross Profit | -- | -- | 537,662 | 438,070 | 332,486 | 275,745 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | (567) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | -- | -- | (395) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | -- | -- | 213,384 | 175,128 | 144,468 | 155,691 | |
| Taxation | -- | -- | (23,335) | (21,900) | (10,635) | (15,246) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | -- | -- | 1,865 | 3,229 | (2,120) | 2,515 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 218,786 | 14.002% | 191,914 | 156,457 | 131,713 | 142,960 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | -- | -- | (6,678) | (8,637) | (12,590) | (13,892) |
| Depreciation & Amortisation | -- | -- | 79,864 | 47,554 | 37,077 | 30,216 |
| Directors' Emoluments | -- | -- | 9,098 | 9,332 | 6,916 | 2,425 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 126.000 | 14.545% | 110.000 | 92.000 | 79.000 | 86.000 |
| DPS (cts) | 23.000 | -- | 0.000 | 27.000 | 24.000 | 26.000 |
| Dividend Payout Ratio (%) | 18.254% | -- | -- | 29.348% | 30.380% | 30.233% |
| Cash flow per share ($) | -- | -- | 1.371 | 1.074 | 1.087 | 0.438 |
| NBV per share ($) | -- | -- | 10.081 | 9.645 | 9.000 | 8.406 |
| Remarks: | Real time quote last updated: 01/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 218,786 |
| %Change | 14.002% |
| EPS / (LPS) | RMB 1.260 |
| NBV Per Share (¥) | RMB -- |